Stock 002422 SICHUAN KELUN PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Sichuan Kelun Pharmaceutical Co., Ltd.

Equities

002422

CNE100000PW7

End-of-day quote Shenzhen S.E.
Other stock markets
 03:30:00 30/04/2024 am IST 		5-day change 1st Jan Change
33.95 CNY +3.41% Intraday chart for Sichuan Kelun Pharmaceutical Co., Ltd. +13.43% +16.87%
25/04 Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
10/04 Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Sichuan Kelun Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for the Year 2023
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
US FDA to Accelerate Review of Kelun Pharma Unit's Lung Cancer Drug
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4%
Kelun Pharmaceutical's Olaparib Tablets Get Nod from Chinese Drug Regulator
Kelun Pharma Gets Registration Approval in China for Immune Thrombocytopenia Drug
Kelun Pharma Sees Up to 50% Jump in 2023 Profit
Kelun Pharma's Unit Gets US FDA's Orphan Drug Designation to A400
Kelun Pharmaceutical's Unit Gains Registration Certificate for Ceftazidime Avibactam Sodium/Sodium Chloride Injection
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
Kelun Pharma Ends Cancer Drug Contract, Revises Partnership With Merck
Merck discontinues some cancer drug development with China's Sichuan Kelun
Kelun Pharma Unit Obtains Registration Approval in China for Bacterial Infection Drug
Sichuan Kelun Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
Sichuan Kelun Pharma to Start License Application Process For New Cancer Drug
Kelun Pharma's Unit Gets Gadobutrol injection Certified
Kelun Pharma Expects Up to 66% Jump in H1 Profit
China's Sichuan Kelun-Biotech opens books for $208 million Hong Kong IPO - term sheet
Kelun Pharma Registers GERD Drug in China
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 002422 Stock
  4. News Sichuan Kelun Pharmaceutical Co., Ltd.
  5. Other languages